Mark M. Jones

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

Georgina V. Long, Reinhard Dummer, Omid Hamid et al. · The Lancet Oncology · 2019 · 944 citations

Medicine, Oncology, Pharmacotherapy +15

Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera

Alessandro M. Vannucchi, Jean‐Jacques Kiladjian, Martin Grießhammer et al. · New England Journal of Medicine · 2015 · 872 citations

Medicine, Hematology, Pharmacology +14

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

Claire Harrison, Alessandro M. Vannucchi, Haifa Kathrin Al‐Ali et al. · Leukemia · 2016 · 509 citations · Full text

Medicine, Hematology, Pharmacology +13

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib et al. · Journal of Hematology & Oncology · 2017 · 427 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial

Srđan Verstovšek, A. M. Vannucchi, Tamás Masszi et al. · Haematologica · 2016 · 156 citations · Full text

Medicine, Hematology, Pharmacology +12